Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | CPT2 | P23786 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6268365 | 1.00 | FFAR1 (0.48) | FFAR1CPT2TDP1CYP4F2CYP4A11 | |
| SCHEMBL11088869 | 1.00 | FFAR1 (0.48) | FFAR1CPT2TDP1CYP4F2CYP4A11 | |
| Gemcadiol SCHEMBL636304 | 1.00 | FFAR1 (0.48) | FFAR1CPT2TDP1CYP4F2CYP4A11 | |
| SCHEMBL11082433 | 1.00 | FFAR1 (0.48) | FFAR1CPT2TDP1CYP4F2CYP4A11 | |
| SCHEMBL6267734 | 1.00 | FFAR1 (0.48) | FFAR1CPT2TDP1CYP4F2CYP4A11 | |
| SCHEMBL6270199 | 0.97 | FFAR1 (0.43) | FFAR1CPT2TDP1ALDH1A1 | |
| Gemcadiol SCHEMBL5097247 | 0.91 | FFAR1 (0.48) | FFAR1CPT2TDP1CYP4F2CYP4A11 | |
| SCHEMBL28002575 | 0.91 | TDP1 (0.42) | FFAR1CPT2TDP1CYP4F2CYP4A11 | |
| SCHEMBL156985 | 0.91 | TDP1 (0.42) | FFAR1CPT2TDP1CYP4F2CYP4A11 | |
| 1,6-Hexanediol SCHEMBL8723953 | 0.91 | TDP1 (0.42) | FFAR1CPT2TDP1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4706956-A1 | LAMINATION STRUCTURE FOR RETORT APPLICATIONS | Siegwerk Druckfarben AG & Co. KGaA (DE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4706954-A1 | DEBONDABLE LAMINATION STRUCTURE FOR RETORT APPLICATION | Siegwerk Druckfarben AG & Co. KGaA (DE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705367-A1 | LAMINATION ADHESIVE | Bostik SA (FR) | 2026-03-11 | — | — | EP | disclosed |
| US-12545823-B2 | Lamination adhesive for sterilisation | BOSTIK SA (FR) | 2026-02-10 | — | — | US | disclosed |
| US-20260002061-A1 | TWO-COMPONENT COMPOSITION | BOSTIK SA (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-3959283-B1 | LAMINATION ADHESIVE FOR STERILISATION | BOSTIK SA (FR) | 2025-10-22 | — | — | EP | disclosed |
| EP-4561826-A1 | METHOD FOR RECYCLING A MULTILAYER SYSTEM | Bostik SA (FR) | 2025-06-04 | — | — | EP | disclosed |
| EP-4561827-A1 | RECYCLED ARTICLE AND USES THEREOF | Bostik SA (FR) | 2025-06-04 | — | — | EP | disclosed |
| EP-4561828-A1 | ADHESIVE COMPOSITION | Bostik SA (FR) | 2025-06-04 | — | — | EP | disclosed |
| EP-4554999-A1 | TWO-COMPONENT COMPOSITION | Bostik SA (FR) | 2025-05-21 | — | — | EP | disclosed |
| WO-2020217023-A1 | LAMINATION ADHESIVE FOR STERILISATION | BOSTIK SA (FR) | 2020-10-29 | — | — | WO | disclosed |
| EP-3724291-A1 | ADHESIVE MULTICOMPONENT COMPOSITION AND USES THEREOF | Bostik SA (FR) | 2020-10-21 | — | — | EP | disclosed |
| US-20200317962-A1 | ADHESIVE MULTICOMPONENT COMPOSITION AND USES THEREOF | BOSTIK SA (FR) | 2020-10-08 | — | — | US | disclosed |
| CN-111433308-A | Multi-component adhesive composition and use thereof | 博斯蒂克股份公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-3658604-A1 | HEAT-CROSSLINKABLE ADHESIVE COMPOSITION | Bostik SA (FR) | 2020-06-03 | — | — | EP | disclosed |
| CN-110914325-A | Thermally crosslinkable adhesive composition | 博斯蒂克股份公司 | 2020-03-24 | — | — | CN | disclosed |
| WO-2019115952-A1 | ADHESIVE MULTICOMPONENT COMPOSITION AND USES THEREOF | BOSTIK SA (FR) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019020943-A1 | HEAT-CROSSLINKABLE ADHESIVE COMPOSITION | BOSTIK SA (FR) | 2019-01-31 | — | — | WO | disclosed |
| US-4454145-A | Nicotinates of alkanediols having hypolipidaemic activity and pharmaceutical compositions containing them | ALFA FARMACEUTICI S.P.A. (IT) | 1984-06-12 | — | — | US | disclosed |
| EP-0064286-A2 | New derivatives of alkanediols having hypolipidaemic activity, methods for their preparation and pharmaceutical compositions containing them | ALFA FARMACEUTICI S.p.A. (IT) | 1982-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545823-B2 | Lamination adhesive for sterilisation | C9, CDH1, RCC1 | FFAR1 909/4885CPT2 4206/4885TDP1 2012/4885 |
| US-20260002061-A1 | TWO-COMPONENT COMPOSITION | SDC2, C9, SDAD1 | FFAR1 2646/4885CPT2 3158/4885TDP1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.